Cargando…
CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study
BACKGROUND: Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) has been described as a biomarker for microglial activation, which were observed increased in a variety of neurological disorders. OBJECTIVE: Our objective was to explore whether genetically de...
Autores principales: | Dong, Ming-Hao, Zhou, Luo-Qi, Tang, Yue, Chen, Man, Xiao, Jun, Shang, Ke, Deng, Gang, Qin, Chuan, Tian, Dai-Shi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985278/ https://www.ncbi.nlm.nih.gov/pubmed/35382840 http://dx.doi.org/10.1186/s12974-022-02443-9 |
Ejemplares similares
-
Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023) -
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
por: Ma, Ling-Zhi, et al.
Publicado: (2020) -
CSF sTREM2: marking the tipping point between preclinical AD and dementia?
por: Schindler, Suzanne E, et al.
Publicado: (2016) -
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline
por: Suárez‐Calvet, Marc, et al.
Publicado: (2018) -
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation
por: Ewers, Michael, et al.
Publicado: (2020)